Evidence map›Paper›PMID 33520931›Full record

ArticleFrontiers in chemistry2020

Deborah Carbonera Guedes, Manuel Hospinal Santiani, Joyce Carvalho, Carlos Ricardo Soccol, João Carlos Minozzo, Ricardo Andrez Machado de Ávila, Juliana Ferreira de Moura, Eliezer Lucas Pires Ramos, Guillermo Raul Castro, Carlos Chávez-Olórtegi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Deborah Carbonera GuedesPrograma de Pós-Graduação Strictu Sensu em Engenharia de Bioprocessos e Biotecnologia, Universidade Federal do Paraná, Curitiba, Brazil.
Manuel Hospinal SantianiPrograma de Pós-Graduação Strictu Sensu em Engenharia de Bioprocessos e Biotecnologia, Universidade Federal do Paraná, Curitiba, Brazil.
Joyce CarvalhoPrograma de Pós-Graduação Strictu Sensu em Engenharia de Bioprocessos e Biotecnologia, Universidade Federal do Paraná, Curitiba, Brazil.
Carlos Ricardo SoccolPrograma de Pós-Graduação Strictu Sensu em Engenharia de Bioprocessos e Biotecnologia, Universidade Federal do Paraná, Curitiba, Brazil.
João Carlos MinozzoPrograma de Pós-Graduação Strictu Sensu em Engenharia de Bioprocessos e Biotecnologia, Universidade Federal do Paraná, Curitiba, Brazil.
Ricardo Andrez Machado de ÁvilaPrograma de Pós Graduação em Ciência da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, Brazil.
Juliana Ferreira de MouraPrograma de Pós-Graduação Strictu Sensu em Engenharia de Bioprocessos e Biotecnologia, Universidade Federal do Paraná, Curitiba, Brazil.
Eliezer Lucas Pires RamosPrograma de Pós-Graduação Strictu Sensu em Engenharia de Bioprocessos e Biotecnologia, Universidade Federal do Paraná, Curitiba, Brazil.
Guillermo Raul CastroLaboratorio de Nanobiomateriales, CINDEFI, Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP)-CONICET (CCT La Plata), La Plata, Argentina.
Carlos Chávez-OlórtegiDepartamento de Bioquímica e Imunologia, Instituto de Ciência Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Vanete Thomaz-SoccolPrograma de Pós-Graduação Strictu Sensu em Engenharia de Bioprocessos e Biotecnologia, Universidade Federal do Paraná, Curitiba, Brazil.
Universidade Federal do Paraná · BRSecretaria da Saúde · BRUniversidade do Extremo Sul Catarinense · BRUniversidade Federal de Minas Gerais · BRUniversidad Nacional de La Plata · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antigen formulation is the main feature for the success of leishmaniosis diagnosis and vaccination, since the disease is caused by different parasite species that display particularities which determine their pathogenicity and virulence. It is desirable that the antigens are recognized by different antibodies and are immunogenic for almost all

Indexed as

cytokinesin vitro infectionleishmaniasismimetic peptidesvaccines

Identifiers

PMID33520931
PMCPMC7843434
OpenAlexW3120885696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.